for a number of reasons, such as keeping FT Sites reliable and secure,
personalising content and ads, providing social media features and to
analyse how our Sites are used.
Make the most of 2022
Lead your own way in business and beyond with our unrivalled journalism.
Add this topic to your myFT Digest for news straight to your inbox
Insurers’ reluctance to pay for Aduhelm treatment forces biotech to lower costs as EMA highlights safety concerns
Executive says patients on other medications will not be able to take competing antiviral treatment
New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?
A successful split of the consumer and pharma divisions would, on paper, unlock value
Reforms included in Biden’s $1.75tn spending bill would see US government negotiate directly with drugmakers
Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people
Bill to allow US government to negotiate lower medicine prices for elderly people fails to advance
Health service to target use of Novartis drug inclisiran in bid to prevent cardiovascular disease in England
UK watchdog finds pharma groups ‘exploited a loophole’ to increase cost of pills by more than 2,000%
UK regulator penalises pharma company and buyout firms Cinven and Hg after NHS hit by ‘unfair’ rises
UK watchdog imposes £260m in penalties for increases in costs of hydrocortisone tablets
US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment
Cases of the deadly infection have soared among coronavirus patients in India and Nepal
Moves to ease market access for generic drugmakers are gaining momentum
Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’
US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line
Lofty prices reward risky, expensive research. But aducanumab’s pricing will raise eyebrows
Campaigners hit out at high price for controversial treatment that has divided scientists
But there are limits to the inroads that biosimilars can make
Suspensions of AstraZeneca’s jab over blood clot concerns are a harbinger of challenges to come
Immunosuppressants tocilizumab and sarilumab also reduce stays in intensive care by at least seven days on average
Gilead’s antiviral drew praise from the White House and a scramble for orders. But does it work?
Online retailer delivers jolt to the healthcare sector but wholesale disruption deemed unlikely
US president says he expects drugmakers to sue over new ‘most favoured nation’ rule